{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:14:06Z","timestamp":1788902046044,"version":"build-2803163510"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Fibroblast activation protein (FAP) is highly expressed in cancer-associated fibroblasts and represents an emerging target for radioligand therapy (RLT). This study aimed to evaluate treatment outcomes of \u00b9\u2077\u2077Lu-FAP-2286 and to investigate whether changes in quantitative parameters on \u2076\u2078Ga-FAP-2286 PET\/CT are associated with treatment response and survival in patients with advanced solid tumors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>In this single-center retrospective study, patients with advanced solid tumors who completed 2 cycles of \u00b9\u2077\u2077Lu-FAP-2286 therapy and underwent both baseline and posttreatment \u2076\u2078Ga-FAP-2286 PET\/CT (8\u201316\u00a0wk after therapy) were included. Maximum standardized uptake value (SUVmax) and total tumor volume (TTV) were quantified using semiautomatic whole-body segmentation. Relative changes (\u0394SUVmax and \u0394TTV) were calculated. RECIST 1.1 served as the clinical reference standard. Receiver operating characteristic analysis assessed the ability of PET-derived changes to discriminate progressive disease. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier analysis and Cox proportional hazards models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Thirty patients (median age, 65\u00a0y; range, 23\u201378\u00a0y) completed 2 cycles of \u00b9\u2077\u2077Lu-FAP-2286 therapy. According to RECIST 1.1, partial response, stable disease, and progressive disease occurred in 6 (20.0%), 11 (36.7%), and 13 (43.3%) patients, respectively. SUVmax and TTV decreased in 46.7% of patients. \u0394SUVmax demonstrated moderate discrimination for RECIST-defined PD (AUC 0.72,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.04). Patients with \u0394SUVmax &lt;30% had significantly longer PFS than those with \u0394SUVmax \u226530% (median 10.3 vs. 4.4\u00a0mo; log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt;0.001). Median OS was not reached in the \u0394SUVmax &lt;30% group compared with 9.8 months in the \u0394SUVmax \u226530% group (log-rank\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.003). In multivariable analysis, \u0394SUVmax remained independently associated with PFS (HR: 5.2, 95% CI 1.5\u20137.8;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.010) and OS (HR: 4.3, 95% CI: 1.3\u201314.1;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      =0.015).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In patients with advanced solid tumors treated with 2 cycles of \u00b9\u2077\u2077Lu-FAP-2286, posttreatment changes in SUVmax on \u2076\u2078Ga-FAP-2286 PET\/CT were associated with treatment response and survival, suggesting potential utility as an imaging biomarker for early response assessment and prognostic stratification.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/rlu.0000000000006588","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:01:03Z","timestamp":1783083663000},"page":"877-884","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Posttreatment \u2076\u2078Ga-FAP-2286 PET\/CT Parameters for Response and Survival Assessment After \u00b9\u2077\u2077Lu-FAP-2286 Radioligand Therapy in Advanced Solid Tumors"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8394-5768","authenticated-orcid":false,"given":"Min","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"},{"name":"Department of Radiology, The Affiliated Traditional Chinese Medicine Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihan","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiling","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2687-6739","authenticated-orcid":false,"given":"Chunyin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9583-3285","authenticated-orcid":false,"given":"Jie","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Magnetic Resonance Imaging, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, PR China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4088-7649","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Affiliated Hospital of Southwest Medical University"},{"name":"Nuclear Medicine and Theranositics Key Laboratory of Sichuan Province"},{"name":"Institute of Nuclear Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"R1-20260908","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1016\/j.cell.2023.03.016","article-title":"Fibroblasts in cancer: unity in heterogeneity","volume":"186","author":"Chhabra","year":"2023","journal-title":"Cell"},{"key":"R2-20260908","doi-asserted-by":"crossref","first-page":"6208","DOI":"10.1158\/1078-0432.CCR-12-0644","article-title":"Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies","volume":"18","author":"Fischer","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R3-20260908","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1021\/acs.molpharmaceut.2c01051","article-title":"Inhibition of poly(ADP-ribose) polymerase sensitizes [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)-mediated radiotherapy in triple-negative breast cancer","volume":"20","author":"Bao","year":"2023","journal-title":"Mol Pharm"},{"key":"R4-20260908","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10555-020-09909-3","article-title":"The role of fibroblast activation protein in health and malignancy","volume":"39","author":"Fitzgerald","year":"2020","journal-title":"Cancer Metastasis Rev"},{"key":"R5-20260908","doi-asserted-by":"crossref","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","article-title":"Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers","volume":"87","author":"Garin-Chesa","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R6-20260908","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R7-20260908","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R8-20260908","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R9-20260908","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [(177)Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-20260908","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1007\/s00259-022-06048-5","article-title":"[(177)Lu]Lu-FAP-2286 therapy in a case of right lung squamous cell carcinoma with systemic metastases","volume":"50","author":"Rao","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R11-20260908","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1007\/s00259-024-06817-4","article-title":"The complete metabolic\/molecular response to chemotherapy combined with [(177)Lu]Lu-FAP-2286 in metastatic breast cancer","volume":"51","author":"Banihashemian","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20260908","doi-asserted-by":"crossref","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","article-title":"First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma","volume":"49","author":"Banihashemian","year":"2024","journal-title":"Clin Nucl Med"},{"key":"R13-20260908","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1007\/s00259-025-07495-6","article-title":"Fibroblast activation protein-targeted PET\/CT using [18 F]FAP-2286 for the evaluation of lung cancer: a comparative study with [18 F]FDG PET\/CT","volume":"53","author":"Ma","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R14-20260908","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/RLU.0000000000006210","article-title":"Exploratory analysis of [ 68 Ga]Ga-FAP-2286 PET\/CT quantitative parameters for predicting response to [ 177 Lu]Lu-FAP-2286 therapy in non-small cell lung cancer","volume":"51","author":"Fan","year":"2026","journal-title":"Clin Nucl Med"},{"key":"R15-20260908","doi-asserted-by":"crossref","first-page":"585","DOI":"10.2967\/jnumed.124.268258","article-title":"Comparison of [(68)Ga]Ga-fibroblast activation protein inhibitor-04 and [(18)F]FDG PET imaging for solitary fibrous tumor and preliminary application of FAP-targeted radiopharmaceutical therapy","volume":"66","author":"Wang","year":"2025","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"R16-20260908","doi-asserted-by":"crossref","first-page":"122s","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J Nucl Med"},{"key":"R17-20260908","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R18-20260908","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu-fibroblast activation protein inhibitor-46 for patients with relapsed or refractory cancers: a preliminary study","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R19-20260908","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin Cancer Res"},{"key":"R20-20260908","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2967\/jnumed.122.264104","article-title":"The prognostic value of posttreatment (68)Ga-PSMA-11 PET\/CT and (18)F-FDG PET\/CT in metastatic castration-resistant prostate cancer treated with (177)Lu-PSMA-617 and NOX66 in a phase I\/II trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"},{"key":"R21-20260908","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1126\/science.1195300","article-title":"Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha","volume":"330","author":"Kraman","year":"2010","journal-title":"Science"},{"key":"R22-20260908","doi-asserted-by":"crossref","first-page":"e007628","DOI":"10.1136\/jitc-2023-007628","article-title":"Total metabolic tumor volume on (18)F-FDG PET\/CT is a game-changer for patients with metastatic lung cancer treated with immunotherapy","volume":"12","author":"Tricarico","year":"2024","journal-title":"J Immunother Cancer"},{"key":"R23-20260908","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3390\/biomedicines13010123","article-title":"PET-assessed metabolic tumor volume across the spectrum of solid-organ malignancies: a review of the literature","volume":"13","author":"Agarwal","year":"2025","journal-title":"Biomedicines"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006588","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:00:40Z","timestamp":1788901240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006588"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":23,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006588","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"2026-04-17","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}